Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors.
Basic Information
ID: ALA4368924
Journal: Bioorg Med Chem Lett
Title: Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors.
Authors: Ma YZ, Tang ZB, Sang CY, Qi ZY, Hui L, Chen SW.
Abstract: To find novel effective Aurora kinases inhibitors, a series of structurally interesting nitroxide labeled pyrimidines were synthesized and evaluated their anti-proliferative and Aurora kinases inhibitory activities. Among them, butyl 2-(3-((5-fluoro-2-((4-((1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl) phenyl) amino)pyrimidin-4-yl)amino)-1H-pyrazol-5-yl)acetate (22) possessed the most potent anti-proliferative effects against four carcinoma cell lines with IC50 values in range of 0.89-11.41 μM, and kinases inhibition against Aurora A and B with the IC50 values were 9.3 and 2.8 nM, respectively. Furthermore, compound 22 blocked the phosphorylation of Aurora A (T288), Aurora B (Thr232) and HisH3, decreased the expression of proteins TPX2, Eg5 and Bora, as well as disrupted the mitotic spindle formation in HeLa cells. Molecular docking studies indicated that compound 22 well interact with both Aurora A and B. The results showed that compound 22 is a potential anticancer agent as promising pan-Aurora kinase inhibitor.
CiteXplore: 30728112
DOI: 10.1016/j.bmcl.2019.01.034
Patent ID: ┄